157 related articles for article (PubMed ID: 29753348)
1. Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
Schlander M; Dintsios CM; Gandjour A
Value Health; 2018 May; 21(5):525-531. PubMed ID: 29753348
[TBL] [Abstract][Full Text] [Related]
2. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
3. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
4. Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
[TBL] [Abstract][Full Text] [Related]
5. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
6. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence.
Angelis A; Tordrup D; Kanavos P
Health Policy; 2015 Jul; 119(7):964-79. PubMed ID: 25661982
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
8. Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria.
Iskrov GG; Jakovljevic MM; Stefanov RS
Folia Med (Plovdiv); 2018 Mar; 60(1):79-91. PubMed ID: 29668449
[TBL] [Abstract][Full Text] [Related]
9. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
10. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
11. An analysis of orphan medicine expenditure in Europe: is it sustainable?
Mestre-Ferrandiz J; Palaska C; Kelly T; Hutchings A; Parnaby A
Orphanet J Rare Dis; 2019 Dec; 14(1):287. PubMed ID: 31829218
[TBL] [Abstract][Full Text] [Related]
12. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
Schlander M; Adarkwah CC; Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
[TBL] [Abstract][Full Text] [Related]
14. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
15. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann BM; Eichinger J; Baumgartner MR
Orphanet J Rare Dis; 2021 Jun; 16(1):292. PubMed ID: 34193232
[TBL] [Abstract][Full Text] [Related]
17. Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales.
Pijeira Perez Y; Wood E; Hughes DA
Orphanet J Rare Dis; 2023 Nov; 18(1):342. PubMed ID: 37915031
[TBL] [Abstract][Full Text] [Related]
18. Impact of orphan drugs on Latvian budget.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
[TBL] [Abstract][Full Text] [Related]
19. Sustainable rare diseases business and drug access: no time for misconceptions.
Rollet P; Lemoine A; Dunoyer M
Orphanet J Rare Dis; 2013 Jul; 8():109. PubMed ID: 23879976
[TBL] [Abstract][Full Text] [Related]
20. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
[Next] [New Search]
